All In Biotech

Drug Trial Radar · NCT07575308

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jun 30, 2027

Study completion Aug 30, 2029

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
May 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Conditions

  • Von Willebrand Disease (VWD)
  • Heavy Menstrual Bleeding (HMB)

Interventions

  • ALN-6400Drug

    ALN-6400 will be administered subcutaneously (SC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse EventsTime frame: Up to Week 72

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Orange, California · Not yet recruiting

  • Clinical Trial Site

    San Diego, California · Not yet recruiting

  • Clinical Trial Site

    San Francisco, California · Not yet recruiting

  • Clinical Trial Site

    Miami, Florida · Recruiting

  • Clinical Trial Site

    Augusta, Georgia · Not yet recruiting

  • Clinical Trial Site

    Lexington, Kentucky · Not yet recruiting

  • Clinical Trial Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Clinical Trial Site

    Cleveland, Ohio · Not yet recruiting

  • Clinical Trial Site

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Clinical Trial Site

    Charleston, South Carolina · Not yet recruiting

  • Clinical Trial Site

    Bad Homburg, Germany · Not yet recruiting

  • Clinical Trial Site

    Berlin, Germany · Not yet recruiting

  • Clinical Trial Site

    Duisburg, Germany · Not yet recruiting

  • Clinical Trial Site

    Frankfurt am Main, Germany · Not yet recruiting

  • Clinical Trial Site

    Nijmegen, Netherlands · Not yet recruiting

  • Clinical Trial Site

    Utrecht, Netherlands · Not yet recruiting

  • Clinical Trial Site

    Stockholm, Sweden · Not yet recruiting

  • Clinical Trial Site

    Istanbul, Turkey (Türkiye) · Not yet recruiting

  • Clinical Trial Site

    Izmir, Turkey (Türkiye) · Not yet recruiting

  • Clinical Trial Site

    Izmir, Turkey (Türkiye) · Not yet recruiting

  • Clinical Trial Site

    Şahinbey, Turkey (Türkiye) · Not yet recruiting

  • Clinical Trial Site

    Samsun, Turkey (Türkiye) · Not yet recruiting

  • Clinical Trial Site

    Birmingham, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    Bradford, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    London, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    London, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    London, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    Oxford, United Kingdom · Not yet recruiting

  • Clinical Trial Site

    Truro, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.